Verastem (VSTM) Stock Price, News & Analysis

Company Overview

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Key Stats

• Today's Range: $5.57 to $5.78
• 50-Day Range: $3.67 to $7.00
• 52-Week Range: $2.10 to $13.82
• Volume: 455,798 shs
• Average Volume: 856,793 shs
• Market Capitalization: $251.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.63
• Consensus Rating: Buy

Verastem Stock Analysis - MarketRank™

Verastem scored higher than 60% of companies evaluated by MarketBeat, and ranked 477th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Verastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Verastem has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Verastem are expected to grow in the coming year, from ($3.02) to ($2.93) per share.

Price to Book Value per Share Ratio

Verastem has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.27% of the float of Verastem has been sold short.

Short Interest Ratio / Days to Cover

Verastem has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Verastem has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verastem does not currently pay a dividend.

Dividend Growth

Verastem does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.27% of the float of Verastem has been sold short.

Short Interest Ratio / Days to Cover

Verastem has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Verastem has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Verastem this week, compared to 3 articles on an average week.

Search Interest

Only 9 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,990.00 in company stock.

Percentage Held by Insiders

Only 2.20% of the stock of Verastem is held by insiders.

Percentage Held by Institutions

88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VSTM Stock Analysis - Frequently Asked Questions

How have VSTM shares performed this year?

Verastem's stock was trading at $5.17 at the beginning of the year. Since then, VSTM stock has increased by 9.3% and is now trading at $5.65.
View the best growth stocks for 2025 here.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.11.

When did Verastem's stock split?

Verastem shares reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Verastem's major shareholders?

Verastem's top institutional investors include Balyasny Asset Management L.P. (8.87%), Nantahala Capital Management LLC (8.43%), AIGH Capital Management LLC (5.99%) and Soleus Capital Management L.P. (4.91%). Insiders that own company stock include Dan Paterson, Brian M Stuglik, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 2/20/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VSTM
• CUSIP: 92337C10
• CIK: 1526119
• Web: www.verastem.com
• Phone: (781) 292-4200
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.63
• High Stock Price Target: $20.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +141.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-87,370,000.00
• Net Margins: N/A
• Pretax Margin: -934.54%
• Return on Equity: -332.73%
• Return on Assets: -73.97%

Debt

• Debt-to-Equity Ratio: 2.77
• Current Ratio: 3.23
• Quick Ratio: 3.23

Sales & Book Value

• Annual Sales: $2.60 million
• Price / Sales: 96.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.27 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 44,510,000
• Free Float: 43,528,000
• Market Cap: $251.48 million
• Optionable: Optionable
• Beta: 0.28